$FHTX News
Last published 1d ago
- 1d agoFHTXGuggenheim 3rd Annual Healthcare Innovation Conference - FOGHORN THERAPEUTICS INCEarnings Call TranscriptsAll right, so welcome to this next Fireside Chat with Foghorn Therapeutics. With us today we have Adrian Gottschalk, President and CEO. Adrian, welcome. Thanks for joining us. Thank you for having me. So, Adrian, after t
- 1d agoFHTXFOGHORN THERAPEUTICS INC. (FHTX) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - FOGHORN THERAPEUTICS INCEarnings Call TranscriptsAll right, so welcome to this next Fireside Chat with Foghorn Therapeutics. With us today we have Adrian Gottschalk, President and CEO. Adrian, welcome. Thanks for joining us. Thank you for having me. So, Adrian, after t
- 1d agoFHTXFOGHORN THERAPEUTICS INC. (FHTX) - FOGHORN THERAPEUTICS INCEarnings Call TranscriptsAll right, so welcome to this next Fireside Chat with Foghorn Therapeutics. With us today we have Adrian Gottschalk, President and CEO. Adrian, welcome. Thanks for joining us. Thank you for having me. So, Adrian, after t
- 2d agoFHTXFoghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate UpdateGlobeNewswire- Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027 - Selective EP300 degrader with potential to treat multiple myeloma (MM) and
- 2d agoFHTXFoghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate UpdateGlobeNewswire- Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027
- 2d agoFHTXFoghorn Therapeutics Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 1w agoFHTXFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in NovemberGlobeNewswireWATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and immunology &
- 3mo agoFHTXFoghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate UpdateGlobeNewswire- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat multiple myeloma
- 4mo agoFHTXStep Pharma announces the appointment of Neil Gallagher as Non-Executive DirectorGlobeNewswireNeil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncologyHis appointment will strengthen Step Pharma’s
- 4mo agoONNVFAZNAPREBOLD+1Next-Generation DNA Repair Therapies Open New Frontiers in OncologyGlobeNewswireAUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which
- 5mo agoFHTXFoghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026GlobeNewswireWATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 6mo agoFHTXFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in MayGlobeNewswireWATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 6mo agoFHTXFoghorn Therapeutics Provides First Quarter 2026 Financial and Corporate UpdateGlobeNewswire- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory - Selective CBP
- 6mo agoFHTXFoghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual MeetingGlobeNewswire- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models - Selective CBP degrader
- 7mo agoFHTXFoghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual MeetingGlobeNewswireNew preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical characterization of FHT-171,
- 8mo agoFHTXFoghorn Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 8mo agoFHTXFoghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial OfficerGlobeNewswireWATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 9mo agoFHTXFoghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech SummitGlobeNewswireWATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 10mo agoONCYNRIXERASFHTX+1Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent CliffPR NewswireEquity-Insider.com News Commentary – The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion toward a...
- 10mo agoFHTXFoghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% PremiumGlobeNewswireWATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 10mo agoFHTXFoghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026GlobeNewswireRecently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase 1 dose-escalation
- 11mo agoGTBPERASFHTXOABI+1Platform Technologies Drive $211B Surge in Precision Cancer TreatmentPR NewswireEquity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies...
- 11mo agoFHTXFoghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 1y agoFHTXFoghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate UpdateGlobeNewswireOngoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered
- 1y agoFHTXFoghorn Therapeutics to Participate in Three Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 1y agoFHTXFoghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader ProgramsGlobeNewswire- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors - Selective CBP
- 1y agoFHTXFoghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity SummitGlobeNewswireCAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 1y agoIQVFHTXMRNASANAIQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences CompaniesPR NewswireIQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, ...
- 1y agoFHTXFoghorn Therapeutics to Participate in Three Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious
- 1y agoFHTXMRNASANAAjit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship PioneeringPR NewswireFlagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer,...
- 1y agoFHTXFoghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate UpdateGlobeNewswireFHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical
- 1y agoFHTXMRNASANAFlagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology PlatformPR NewswireFlagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions...
- 1y agoFHTXFoghorn Therapeutics to Participate in Four Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 1y agoFHTXFoghorn Therapeutics Provides First Quarter 2025 Financial and Corporate UpdateGlobeNewswireFHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity
- 1y agoFHTXMRNASANATed Myles Joins Cellarity as Chief Executive OfficerPR NewswireCellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today...
- 1y agoFHTXFoghorn Therapeutics to Participate in the Citizens Life Sciences ConferenceGlobeNewswireCAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 1y agoFHTXFoghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 1y agoFHTXMRNASANAFlagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient TherapeuticsPR NewswireFlagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul ...
- 1y agoFHTXFoghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline UpdateGlobeNewswire- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909
- 1y agoFHTXMRNASANAFlagship Pioneering Unveils Etiome to Pioneer Preemptive HealthcarePR NewswireFlagship Pioneering, the bioplatform innovation company, today unveiled Etiome, a company redefining how we detect and preempt disease progression....
- 1y agoFHTXFoghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual MeetingGlobeNewswireCompany to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population Additional
- 1y agoFHTXMRNASANAFlagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune DiseasePR NewswireFlagship Pioneering, the bioplatform innovation company, today announced an agreement between Pioneering Medicines, Flagship's in-house drug...
- 1y agoFHTXFoghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR MeetingGlobeNewswire- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical data for FHD-909
- 1y agoCRLFHTXMRNASANACharles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery PlatformBusiness WireFirst Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering's in-house drug development unit Charles River Laboratories International,
- 1y agoFHTXMRNASANAFlagship Pioneering Unveils Lila Sciences to Build Superintelligence in SciencePR NewswireFlagship Pioneering, the bioplatform innovation company, today unveiled Lila Sciences, a company building the world's first scientific...
- 1y agoFHTXFoghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic OutlookGlobeNewswireFirst-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
- 1y agoFHTXFoghorn Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
- 1y agoFHTXMRNASANAFlagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio HealthPR NewswireFlagship Pioneering, the bioplatform innovation company, and YourBio Health, a pioneer in remote blood collection technology, today announced the...
- 1y agoFHTXMRNAOMGASANAFlagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and InnovationPR NewswireFlagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University Health ...
- 1y agoFHTXMRNAOMGASANAFlagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and InnovationPR NewswireFlagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University Health ...